Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery

NCT02893930 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

13

Enrollment

NIH

Sponsor class

Conditions

Pancreatic Neuroendocrine Tumor G1
Pancreatic Neuroendocrine Tumor G2
Refractory Pancreatic Neuroendocrine Carcinoma

Interventions

DRUG: Sapanisertib

Sponsor

National Cancer Institute (NCI)